Finerenone in Patients With a Recent Worsening Heart Failure Event
Compared with those without recent WHF, patients with HF and mildly reduced or preserved ejection fraction who have experienced a recent WHF event are at higher risk for recurrent HF events and CV death; a possible signal of enhanced absolute treatment benefit with finerenone in this population requires further confirmation in future studies. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] & Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; A study to gather information on the influence of study drug finerenone on the number of deaths and hospitalizations in participants with heart failure EudraCT 2020-000306-29).
Authors
- Sanjiv J. Shah (ORCID: https://orcid.org/0000-0002-5655-8201)
- Brian Lee Claggett (ORCID: https://orcid.org/0000-0002-4215-9218)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- James Lay‐Flurrie
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Katja Rohwedder
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Maria Borentain
- Michele Senni (ORCID: https://orcid.org/0000-0001-5502-7882)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Ian J. Kulac (ORCID: https://orcid.org/0000-0002-0710-1088)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- Jonathan W. Cunningham (ORCID: https://orcid.org/0000-0003-4481-7867)
- Akshay S. Desai (ORCID: https://orcid.org/0000-0002-1443-0701)
- Mikhail Kosiborod
- Prabhakar Viswanathan
- Bertram Pitt
- Flaviana Amarante
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Bayer (United States) (US)
- National University of Singapore (SG)
- University of Groningen (NL)
- University of Michigan (US)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- Saint Luke's Hospital (US)
- National Heart Centre Singapore (SG)
- Bayer (France) (FR)
- Bayer (United Kingdom) (GB)
- University of Milano-Bicocca (IT)
- Bayer (Germany) (DE)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.jacc.2024.09.004
- Citations
- 30
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 12.06
Funders
- Pharmaceuticals Bayer